PDUFA V: Patients’ Opinions Could Get Formal Role In Review Decisions
Executive Summary
FDA is looking to formally add patient perspectives to its analyses in drug application reviews as it continues exploring a more transparent risk-benefit analysis.
You may also be interested in...
PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment
The Pharmaceutical Research and Manufacturers of America’s Benefit-Risk Action Team expects to complete pilot testing of a framework for conducting benefit-risk assessments by the end of 2011.
PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment
The Pharmaceutical Research and Manufacturers of America’s Benefit-Risk Action Team expects to complete pilot testing of a framework for conducting benefit-risk assessments by the end of 2011.
FDA, CMS To Standardize Regulatory Analytical Tools
FDA, CMS and other agencies within the Department of Health and Human Services will combine forces to improve and standardize analytical tools used in regulatory decision-making.